Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD

  • Price D
  • Gray A
  • Gale R
 et al. 
  • 58


    Mendeley users who have this article in their library.
  • 29


    Citations of this article.


Introduction: Indacaterol is a novel inhaled once-daily long-acting beta2-agonist (LABA) for the maintenance treatment of COPD that has been compared to existing inhaled monotherapies on a number of symptomatic endpoints in clinical studies. With constrained healthcare budgets, the objective of this analysis was to evaluate the cost-effectiveness of indacaterol 150 μg, the approved starting dose for maintenance therapy, from a German heath service perspective against the most widely used bronchodilator tiotropium, and the twice-daily LABA, salmeterol. Methods: A Markov model was developed with the following main health states: Mild, Moderate, Severe, and Very Severe COPD, based on pre-bronchodilator FEV1measures reported in the indacaterol clinical trials, and death. Each disease severity health state had two associated health states for severe or non-severe exacerbation. The model considered patients with moderate to severe COPD, with a mean age of 64 years. The base case time horizon was three years, with discounting set at 3% for costs and benefits. Selected clinical inputs and health state utilities were derived from indacaterol clinical trials, while costs were based on publicly available drug prices and tariffs or published sources. Inputs describing disease progression were based on published data on the rate of FEV1decline. Results: Point-estimates show that indacaterol 150 μg is dominant (lower total costs and better outcomes) against tiotropium and salmeterol. An alternative analysis comparing indacaterol 300 μg (maximum dose) against tiotropium, showed an incremental cost-effectiveness ratio (ICER) of approximately €28,300 per QALY. Conclusion: Indacaterol is cost-effective compared to tiotropium and salmeterol. © 2011 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • Bronchodilator
  • COPD
  • Cost-Effectiveness Analysis
  • QALYs

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • David Price

  • Alastair Gray

  • Rupert Gale

  • Yumi Asukai

  • Laura Mungapen

  • Adam Lloyd

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free